Q2 Earnings Forecast for Septerna Issued By HC Wainwright

Septerna, Inc. (NASDAQ:SEPN - Free Report) - HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Septerna in a research note issued to investors on Monday, June 23rd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of $0.09 for the quarter. HC Wainwright currently has a "Buy" rating and a $26.00 target price on the stock. The consensus estimate for Septerna's current full-year earnings is ($7.11) per share. HC Wainwright also issued estimates for Septerna's Q3 2025 earnings at $0.72 EPS, Q4 2025 earnings at $0.68 EPS, FY2025 earnings at $1.01 EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($2.46) EPS.

A number of other equities analysts also recently weighed in on SEPN. Wells Fargo & Company upped their target price on Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a report on Friday, May 16th. Cantor Fitzgerald increased their target price on shares of Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $26.75.

Septerna Stock Performance

Shares of SEPN stock traded down $0.36 on Wednesday, reaching $10.51. 1,123,979 shares of the company's stock traded hands, compared to its average volume of 695,041. The business's 50 day moving average price is $8.94 and its two-hundred day moving average price is $11.41. Septerna has a 12-month low of $4.17 and a 12-month high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The firm had revenue of $0.22 million during the quarter.

Institutional Investors Weigh In On Septerna

Several large investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC bought a new stake in Septerna in the fourth quarter worth approximately $25,000. New York State Common Retirement Fund bought a new stake in Septerna in the fourth quarter worth approximately $32,000. Legal & General Group Plc bought a new stake in Septerna in the fourth quarter worth approximately $42,000. Summit Investment Advisors Inc. bought a new stake in Septerna in the fourth quarter worth approximately $45,000. Finally, KLP Kapitalforvaltning AS bought a new stake in Septerna in the first quarter worth approximately $49,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.